Meiragtx Holdings Plc (MGTX)
NASDAQ:MGTX
MGTX Stock Chart & Stats
$7.41
-$0.03(-0.47%)
At close: 4:00 PM EST
$7.41
-$0.03(-0.47%)
Day’s Range― - ―
52-Week Range$4.55 - $9.73
Previous CloseN/A
Volume124.17K
Average Volume (3M)341.94K
Market Cap
$615.76M
Enterprise Value$669.66M
Total Cash (Recent Filing)$14.84M
Total Debt (Recent Filing)$88.06M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding80,490,890
10 Day Avg. Volume395,771
30 Day Avg. Volume341,939
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)6.27
Price to Sales (P/S)12.78
P/FCF Ratio-3.89
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue24.42
Enterprise Value/Gross Profit59.56
Enterprise Value/Ebitda-4.67
Forecast
1Y Price Target
$14.00Price Target Upside88.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.13
Revenue Forecast (FY)$124.69M
Bulls Say, Bears Say
Bulls Say
Strategic CollaborationThe collaboration with Eli Lilly provides a $75 million upfront payment and potential milestone payments, enhancing MeiraGTx's revenue streams and solidifying its leadership in genetic medicine.
Revenue GrowthA substantial revenue growth rate indicates strong market demand for MeiraGTx's gene therapy products, supporting long-term business expansion and sustainability.
Market PositionSuccess in the AAV-AIPL1 program for vision restoration highlights MeiraGTx's innovative edge and strengthens its competitive position in the gene therapy market.
Bears Say
Financial InstabilityThe negative equity and high leverage indicate financial instability, which can hinder MeiraGTx's ability to invest in R&D and limit operational flexibility.
Profitability ChallengesPersistent negative profit margins reflect ongoing struggles to achieve profitability, necessitating significant improvements in cost management and revenue generation.
Cash Flow DifficultiesNegative cash flows highlight challenges in generating sufficient cash to support operations, increasing reliance on external financing and impacting long-term viability.
Meiragtx Holdings News
MGTX FAQ
What was Meiragtx Holdings Plc’s price range in the past 12 months?
Meiragtx Holdings Plc lowest stock price was $4.55 and its highest was $9.73 in the past 12 months.
What is Meiragtx Holdings Plc’s market cap?
Meiragtx Holdings Plc’s market cap is $615.76M.
When is Meiragtx Holdings Plc’s upcoming earnings report date?
Meiragtx Holdings Plc’s upcoming earnings report date is May 07, 2026 which is in 43 days.
How were Meiragtx Holdings Plc’s earnings last quarter?
Currently, no data Available
Is Meiragtx Holdings Plc overvalued?
According to Wall Street analysts Meiragtx Holdings Plc’s price is currently Undervalued.
Does Meiragtx Holdings Plc pay dividends?
Meiragtx Holdings Plc does not currently pay dividends.
What is Meiragtx Holdings Plc’s EPS estimate?
Meiragtx Holdings Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Meiragtx Holdings Plc have?
Meiragtx Holdings Plc has 80,490,890 shares outstanding.
What happened to Meiragtx Holdings Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Meiragtx Holdings Plc?
Currently, no hedge funds are holding shares in MGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meiragtx Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (88.93% Upside)
$14.00 (88.93% Upside)
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.19%
12-Months-Change
Fundamentals
Return on Equity
-1065.47%
Trailing 12-Months
Asset Growth
-36.73%
Trailing 12-Months
Company Description
Meiragtx Holdings Plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
MGTX Stock 12 Month Forecast
Average Price Target
$14.00
▲(88.93% Upside)
Technical Analysis
Ownership Overview
17.49% Insiders
2.19% Mutual Funds
63.45% Other Institutional Investors
13.26% Public Companies and
Individual Investors